At the age of seven, Demetri Maxim faced a challenging time when his mother’s kidneys failed, leading her to undergo dialysis multiple times a week. Following a successful kidney transplant, it was revealed that Maxim had inherited Polycystic Kidney Disease (PKD) from her, sparking his determination to find a cure for himself and others.
Approximately one in seven Americans suffers from Chronic Kidney Disease (CKD), with around 10% of cases being attributed to genetic factors. Maxim’s passion for discovering a remedy for kidney diseases began during his high school years, fueled by a groundbreaking study in 2021 that demonstrated the potential reversibility of PKD in mice using CRISPR technology.
In light of this discovery, Maxim, a graduate student in computational biology at Stanford, embarked on kidney research under the guidance of Professor Vivek Bhalla. Despite his belief in the efficacy of gene therapy to combat PKD, the main obstacle lay in delivering drugs directly to affected cells.
To address this crucial issue, Maxim established Nephrogen in 2022, a biotech startup utilizing AI and advanced screening techniques to develop a specialized drug delivery system tailored to target kidney cells precisely. Nephrogen has emerged as a top contender in the Startup Battlefield segment of TechCrunch Disrupt 2025, showcasing its innovative approach.
Following three years of intensive development, Nephrogen claims to have devised a delivery mechanism that is 100 times more efficient in transporting medication to the kidney compared to existing FDA-approved methods. The next milestone for Nephrogen involves advancing its novel delivery system and proprietary drug into clinical trials, slated to commence in 2027, with plans to secure a $4 million seed funding round to support this endeavor.
Maxim, driven by his personal battle with PKD, aims to participate in the upcoming clinical study, highlighting the challenges he faces due to the disease’s symptoms. He underscores the persistent back pain, frequent hospital visits, and the limited effectiveness of current treatments, emphasizing the looming possibility of requiring dialysis in the future.
Given the profound impact of PKD on his life, Maxim views Nephrogen’s innovative approach as a beacon of hope, potentially offering a definitive cure for the disease. The success of Nephrogen’s pioneering efforts holds the promise of transforming the landscape of kidney disease treatment, offering renewed hope to countless individuals grappling with similar conditions.
If you wish to delve deeper into Nephrogen’s groundbreaking work and explore a myriad of innovative pitches, attend informative workshops, and forge valuable connections driving business outcomes, consider attending this year’s Disrupt event from October 27 to 29 in San Francisco.
